Founded in 2005, Beijing Hotgen Biotech Co., Ltd. is a leading high-tech biopharmaceutical and in vitro diagnostics (IVD) enterprise, listed on the STAR Market of the Shanghai Stock Exchange (Stock Code: 688068). With a strong R&D foundation, Hotgen integrates innovation from its Institute of Future Technology, focusing on nucleic acid and antibody drugs, as well as biotechnology-based health and beauty products.
The company’s IVD portfolio includes the UPT point-of-care testing series, MQ60 chemiluminescence analyzers, and C800 high-throughput CLIA systems, covering more than 100 diagnostic parameters across key disease areas. Its products hold over 600 international certifications, including CE IVDR, NMPA, BfArM, and MHRA approvals.
Guided by the mission “Developing Biotechnology and Benefiting Human Health,” Hotgen continues to expand globally through subsidiaries in Europe, India, and the Americas, advancing innovations that improve human health and diagnostic efficiency worldwide.
No. 55 Qingfeng West Road, Daxing District, Beijing, Beijing, China